Recce Pharmaceuticals (ASX:RCE) Trading Up 4.8%

Recce Pharmaceuticals Ltd (ASX:RCE)’s stock price was up 4.8% during trading on Friday . The company traded as high as A$0.22 ($0.16) and last traded at A$0.22 ($0.16), approximately 53,764 shares changed hands during trading. The stock had previously closed at A$0.21 ($0.15).

The company has a current ratio of 0.09, a quick ratio of 0.08 and a debt-to-equity ratio of 0.41. The stock has a fifty day moving average of A$0.22. The stock has a market capitalization of $23.57 million and a P/E ratio of -11.58.

In related news, insider Michele Dilizia sold 277,000 shares of the firm’s stock in a transaction that occurred on Wednesday, August 7th. The stock was sold at an average price of A$0.22 ($0.15), for a total value of A$60,109.00 ($42,630.50).

Recce Pharmaceuticals Company Profile (ASX:RCE)

Recce Pharmaceuticals Ltd, a biotechnology company, researches and develops antibiotic drugs in Australia. The company focuses on the development of RECCE 327 that helps to address the problem of antibiotic resistant superbugs. It also develops drugs for the treatment of stomach ulcers and diarrhea. The company was formerly known as Recce Limited and changed its name to Recce Pharmaceuticals Ltd in November 2017.

Recommended Story: What is Elliott Wave theory?

Receive News & Ratings for Recce Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Recce Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.